Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org .
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There have been two reported cases of remission of immune checkpoint inhibitor-associated diabetes mellitus.
“There have been two reported cases of ICI-DM remission 76,77”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 205 · Cited by 570
Part of this paper’s reference list could not be split into single entries.
Research works printed but not linked: 1
- Reimold AM. TNFalpha as therapeutic target: new drugs, more appli- cations. Curr Drug Targets Inflamm Allergy 2002;1:377-392.
- Authors
- Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Hoffner, B., Hoimes, C. J., Lacouture, M., Locke, F., Lunning, M., Mohindra, N. A., Naidoo, J., Olszanski, A. J., Oluwole, O., Patel, S. P., Reddy, S., Ryder, M., Santomasso, B., Shofer, S., Sosman, J. A., Wahidi, M., Wang, Y., Johnson-Chilla, A., & Scavone, J. L.
- Affiliations
- Seattle Cancer Care Alliance (US)
- University of Michigan (US)
- Johns Hopkins University (US)
- Moffitt Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
- City Of Hope National Medical Center (US)
- University of Alabama at Birmingham (US)
- Smilow Cancer Hospital (US)
- Roswell Park Comprehensive Cancer Center (US)
- Massachusetts General Hospital (US)
- University of Colorado Cancer Center (US)
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Fred and Pamela Buffett Cancer Center (US)
- Fox Chase Cancer Center (US)
- Vanderbilt-Ingram Cancer Center (US)
- Moores Cancer Center (US)
- Stanford Cancer Institute (US)
- Mayo Clinic (US)
- Duke Cancer Institute (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Comprehensive Cancer Network (US)
- ORCID
- Thompson, John A.
- Schneider, Bryan J.
- Brahmer, Julie
- Armand, Philippe
- Bhatia, Shailender
- Budde, Lihua E.
- Costa, Luciano
- Ernstoff, Marc S.
- Frigault, Matthew
- Hoimes, Christopher J.
- Lacouture, Mario
- Locke, Frederick
- Lunning, Matthew
- Mohindra, Nisha A.
- Naidoo, Jarushka
- Olszanski, Anthony J.
- Oluwole, Olalekan
- Patel, Sandip P.
- Reddy, Sunil
- Ryder, Mabel
- Santomasso, Bianca
- Shofer, Scott
- Sosman, Jeffrey A.
- Wahidi, Momen
- Wang, Yinghong
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2019-03-11
- Volume
- 17
- Issue
- 3
- Pages
- 255-289
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2924070172
- Cited by
- 570
- References
- 205
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 65 · 2023: 69 · 2022: 98 · 2021: 106 · 2020: 117 · 2019: 44 · 2018: 5
- FWCI
- 38.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the National Comprehensive Cancer Network (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune-related adverse events, cancer immunotherapy, immune checkpoint inhibitors, immune-related pneumonitis, immune-related colitis, immune-related endocrinopathy, immune-related nephritis, immune-related hypothyroidism
- MeSH terms
- Antineoplastic Agents, Immunological, Humans, Neoplasms, Disease Management, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
